Eli Lilly and Co. and BioNTech AG have entered a research collaboration to discover novel cancer immunotherapies. The companies will collaborate to identify and validate tumor targets and their corresponding T cell receptors (TCRs) in one or more types of cancer. These tumor targets and TCRs may then be engineered and developed into potent and selective cancer therapies. BioNTech will receive a $30 million signing fee and for each potential drug, and is eligible for more than $300 million in d...